Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Clinical trial NCT05698199 · COMPLETED
Trial details
- NCT number
- NCT05698199
- Sponsor
- Immunomic Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-21
- Primary completion
- 2026-02-11
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.